Blueprint Medicines (BPMC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BPMC Blueprint Medicines

Watchlist

90.140
+1.210+1.36%

Close Dec 20 16:00 ET

90.000
-0.140-0.16%

Post 16:55 ET

5.73BMarket Cap-43.13P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

J.P. Morgan's Top Healthcare Stocks for 2025
Seeking AlphaDec 20 11:30 ET
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireDec 18 08:00 ET
Express News | Guggenheim Reiterates Buy on Blueprint Medicinesto Buy
BenzingaDec 11 11:58 ET
Blueprint Medicines Analyst Ratings
BenzingaDec 9 11:02 ET · Ratings
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Moomoo NewsDec 9 04:32 ET · Ratings
Express News | Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
BenzingaDec 9 03:43 ET

Comments

Stock_Drift

Apr 11 20:13

Extended Hours Top Moovers.

$Gryphon Digital Mining (GRYP.US)$ $Zimmer Biomet Holdings (ZBH.US)$ $Cohu Inc (COHU.US)$ $Evolv Technologies (EVLV.US)$ $Brookfield (BN.US)$ $VACASA INC (VCSA.US)$ $Blueprint Medicines (BPMC.US)$ $Williams-Sonoma (WSM.US)$ $U.S. Century Bank (USCB.US)$
📊⚡️📊

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Mar 15 06:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

Feb 19 12:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

Jan 29 09:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.

Blueprint Medicines Corporation's (NASDAQ:BPMC) Shareholders Might Be Looking For Exit

Heat List

Overall

No Data

Investment Theme

Cancer Research

Intraday+0.56%